CompareRetinAIvsSully.ai

RetinAI is an ophthalmology data and AI company that manages imaging and supports analysis across eye care and research. The product is positioned around retinal screening and care routing rather than ophthalmologist replacement, and specialist follow-up remains essential for every positive screen surfaced through the workflow. Buyers should confirm regulatory clearance, camera and imaging hardware compatibility, downstream referral integration, and program reporting before launching diabetic eye screening across primary care sites today.

Buyers usually compare RetinAI for ophthalmic data management plus AI analysis, with eye care clinics and research programs as the core audience. The trade-off to keep in mind: value tied to imaging data workflow. Pricing is sales-led and scoped per buyer rather than posted publicly. A focused pilot, scoped to one workflow, is usually the cleanest way to test fit.

Sully.ai is an AI medical scribe and clinical assistant that drafts notes from patient visits and supports related documentation tasks. The product is positioned around ambient capture, structured note drafting, and EHR workflow rather than autonomous documentation, and clinician review of every drafted note remains essential before sign-off. Buyers should confirm specialty fit, EHR integration depth, documentation accuracy, and clinician training plan before scaling rollout across teams.

Buyers usually compare Sully.ai for an all-in-one AI clinician assistant approach, with clinics and physician practices as the core audience. The trade-off to keep in mind: specialty depth varies across practice types. Pricing is sales-led and scoped per buyer rather than posted publicly. A focused pilot, scoped to one workflow, is usually the cleanest way to test fit.